Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular disease.

Next Previous
X
Search
Trial Profile

A Phase I/II open label study to assess efficacy and safety of IPH1101 associated with low dose of interleukin 2, as add-on therapy to imatinib in CML patients with residual molecular disease.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IPH 1101 (Primary) ; Interleukin-2
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Innate Pharma

    • Most Recent Events

    • 04 Jul 2012 Official title amended and lead trial centre identified as reported by EudraCT.
    • 04 Jul 2012 Planned End Date 11 Apr 2009 added as reported by EudraCT.
    • 04 Jul 2012 Actual initiation date 11 Oct 2007 added added as reported by EudraCT.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top